Comprehensive analysis of the main effects of Teritusumab/Telivac

Teritusumab (Teclistamab-cqyv) is an innovative bispecific antibody drug mainly used to treat relapsed or refractory multiple myeloma (MM). As aCD3-T cell engager, teritolumab has a unique mechanism of action and can target two molecules at the same time: B cell maturation antigen (BCMA) and T cell receptor (CD3). Through the targeted combination of these two molecules, teritusumab can effectively mobilize the patient's immune system for anti-cancer treatment, especially those who have experienced at least four different treatment regimens, including proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies.

The bispecific nature of teritusumab enables it to simultaneously bind to BCMA and CD3 at the same time, which provides a new therapeutic strategy for the treatment of multiple myeloma. BCMA is an important antigen on the surface of multiple myeloma cells, and CD3 is an important receptor on the surface of T cells. By binding to BCMA, teritusumab directs T cells next to myeloma cells, activating the T cell anti-tumor response and thereby destroying the tumor cells. This mechanism can not only effectively kill cancer cells, but also improve the anti-cancer ability of the patient's immune system.

Teritusumab is indicated for patients with multiple myeloma who are resistant or ineffective to traditional treatments (such as proteasome inhibitors, immunomodulators or anti-CD38 monoclonal antibodies). Clinical trials have shown that teritusumab can significantly improve the overall response rate and progression-free survival in patients with relapsed or refractory multiple myeloma, especially those who have received multiple prior treatment regimens.

In clinical studies, teritusumab has demonstrated significant efficacy. Particularly among patients with relapsed or refractory multiple myeloma, most of the patients treated with teritusumab showed better response. Studies have shown that teritusumab can not only effectively control the disease and reduce the proliferation of myeloma cells, but also prolong the survival of patients. Although some side effects may occur during treatment, the side effects of teritusumab are generally controllable compared with other traditional treatments.

Keyword tags: teritusumab,Teclistamab, relapsed multiple myeloma, B cell maturation antigen, multiple myeloma treatment

Reference materials:https://www.tecvayli.com/